Systematic analysis of berberine-induced signaling pathway between miRNA clusters and mRNAs and identification of mir-99a∼125b cluster function by seed-targeting inhibitors in multiple myeloma cells

References

• Jantova S, Cipak L, Cernakova M, Kost'alova D. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol 2003; 55:1143-9; PMID:12956905; http://dx.doi.org/10.1211/002235703322277186
   PubMedGoogle Scholar
• Hwang JM, Kuo HC, Tseng TH, Liu JY, Chu CY. Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Arch Toxicol 2006; 80:62-73; PMID:16189662; http://dx.doi.org/10.1007/s00204-005-0014-8
   PubMed Web of Science ®Google Scholar
• Jabbarzadeh Kaboli P, Rahmat A, Ismail P, Ling KH. Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol 2014; 740:584-95. Epub 2014 Jun 26; PMID:24973693; http://dx.doi.org/10.1016/j.ejphar.2014.06.025
   PubMed Web of Science ®Google Scholar
• Chen FL, Yang ZH, Liu Y, Li LX, Liang WC, Wang XC, Zhou WB, Yang YH, Hu RM. Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine 2008; 33(3): 331-7; PMID:19034703; http://dx.doi.org/10.1007/s12020-008-9089-3
   PubMed Web of Science ®Google Scholar
• Kim S, Kim Y, Kim JE, Cho KH, Chung JH. Berberine inhibits TPA-induced MMP-9 and IL-6 expression in normal human keratinocytes. Phytomedicine 2008; 15:340-7; PMID:17951041; http://dx.doi.org/10.1016/j.phymed.2007.09.011
   PubMed Web of Science ®Google Scholar
• Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 2009; 374 (9686): 324-39; PMID:19541364; http://dx.doi.org/10.1016/S0140-6736(09)60221-X
   PubMed Web of Science ®Google Scholar
• Fonseca R, Barlogie B, Bataille R, Bergsagel PL, Chesi M, Davies FE, Drach J, Greipp PR, Kirsch IR, Kuehl WM, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64(4): 1546-58; PMID:14989251; http://dx.doi.org/10.1158/0008-5472.CAN-03-2876
   PubMedGoogle Scholar
• Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006a; 25(46): 6202-10; PMID:17028600; http://dx.doi.org/10.1038/sj.onc.1209910
   PubMedGoogle Scholar
• Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res 2006b; 66(15): 7390-4; PMID:16885332; http://dx.doi.org/10.1158/0008-5472.CAN-06-0800
   PubMed Web of Science ®Google Scholar
• Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, et al. Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood 2009; 114 (25): e20-26; PMID:19846888; http://dx.doi.org/10.1182/blood-2009-08-237495
   PubMedGoogle Scholar
• Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007; 6:60; PMID:17894887; http://dx.doi.org/10.1186/1476-4598-6-60
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6:259-69; PMID:16557279; http://dx.doi.org/10.1038/nrc1840
   PubMed Web of Science ®Google Scholar
• Wang X. Composition of seed sequence is a major determinant of microRNA targeting patterns. Bioinformatics 2014; 30(10):1377-83. Epub 2014 Jan 26; PMID:24470575; http://dx.doi.org/10.1093/bioinformatics/btu045
   PubMedGoogle Scholar
• Obad S, dos Santos CO, Petri A, Heidenblad M, Broom O, Ruse C, Fu C, Lindow M, Stenvang J, Straarup EM, et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 2011; 43(4): 371-8; PMID:21423181; http://dx.doi.org/10.1038/ng.786
   PubMedGoogle Scholar
• Rossi M, Amodio N, Di Martino MT, Tagliaferri P, Tassone P, Cho WC. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches. Curr Pharm Biotechnol 2014; 15(5): 459-67; PMID:24846067; http://dx.doi.org/10.2174/1389201015666140519104743
   PubMed Web of Science ®Google Scholar
• Pichiorri F1, De Luca L, Aqeilan RI. MicroRNAs: new players in multiple myeloma. Front Genet 2011; 24:2:22; PMID:22303318
   PubMedGoogle Scholar
• Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of mul-tiple myeloma. Best Pract Res Clin Haematol 2007; 20:571-96; PMID:18070707; http://dx.doi.org/10.1016/j.beha.2007.08.004
   PubMed Web of Science ®Google Scholar
• Saha MN, Micallef J, Qiu L, Chang H. Pharmacological activation of the p53 pathway in haematological malignancies. J Clin Pathol 2010; 63(3): 204-9; PMID:19955555; http://dx.doi.org/10.1136/jcp.2009.070961
   PubMedGoogle Scholar
• Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD, Qiu L, Chang H. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One 2012; 7(1): e30215; PMID:22276160; http://dx.doi.org/10.1371/journal.pone.0030215
   PubMed Web of Science ®Google Scholar
• Teoh PJ, Chung TH, Sebastian S, Choo SN, Yan J, Ng SB, Fonseca R, Chng WJ. p53 haploinsufficiency and functional abnormalities in multiple myeloma. Leukemia 2014; 28:2066-74; Mar 14. [Epub ahead of print]; PMID:24625551; http://dx.doi.org/10.1038/leu.2014.102
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell 2010; 18:367-81; PMID:20951946; http://dx.doi.org/10.1016/j.ccr.2010.09.005
   PubMed Web of Science ®Google Scholar
• Kumar M, Lu Z, Takwi AA, Chen W, Callander NS, Ramos KS. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene 2011; 30(7): 843-53; PMID:20935678; http://dx.doi.org/10.1038/onc.2010.457
   PubMed Web of Science ®Google Scholar
• Gordon MW, Yan F, Zhong X, Mazumder PB, Xu-Monette ZY, Zou D, Young KH, Ramos KS, Li Y. Regulation of p53-targeting microRNAs by polycyclic aromatic hydrocarbons: implications in the etiology of multiple myeloma. Mol Carcinog 2014; May 6. [Epub ahead of print]; PMID:24798859; http://dx.doi.org/10.1002/mc.22175
   PubMedGoogle Scholar
• Murray MY, Rushworth SA, Zaitseva L, Bowles KM, Macewan DJ. Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression. Cell Cycle 2013; 12(13): 2144-53; PMID:23759586; http://dx.doi.org/10.4161/cc.25251
   PubMed Web of Science ®Google Scholar
• Peng H, Wen J, Li H, Chang J, Zhou X. Drug inhibition profile prediction for NFκB pathway in multiple myeloma. PLoS One 2011; 6(3): e14750; PMID:21408099; http://dx.doi.org/10.1371/journal.pone.0014750
   PubMedGoogle Scholar
• Peng H, Peng T, Wen J, Engler DA, Matsunami RK, Su J, Zhang L, Chang CC, Zhou X. Characterization of p38 MAPK Isoforms for Drug Resistance Study Using Systems Biology Approach. Bioinformatics 2014; 30(13):1899-907. Epub 2014 Mar 10; PMID:24618474; http://dx.doi.org/10.1093/bioinformatics/btu133
   PubMedGoogle Scholar
• Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, Roccaro AM, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood 2009; 114(3): 619-29; PMID:19443661; http://dx.doi.org/10.1182/blood-2009-01-199281
   PubMed Web of Science ®Google Scholar
• García-Bernal D, Redondo-Muñoz J, Dios-Esponera A, Chèvre R, Bailón E, Garayoa M, Arellano-Sánchez N, Gutierrez NC, Hidalgo A, García-Pardo A, et al. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function. J Pathol 2013; 229(1): 36-48; PMID:22711564; http://dx.doi.org/10.1002/path.4066
   PubMedGoogle Scholar
• Sekiguchi N, Ootsubo K, Wagatsuma M, Midorikawa K, Nagata A, Noto S, Yamada K, Takezako N. The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib / dexamethasone therapy. Int J Hematol 2014; 99(3): 288-95; PMID:24496825; http://dx.doi.org/10.1007/s12185-014-1514-1
   PubMedGoogle Scholar
• Affer M, Chesi M, Chen WD, Keats JJ, Demchenko YN, Tamizhmani K, Garbitt VM, Riggs DL, Brents LA, Roschke AV, et al. Promiscuous rearrangements of the MYC locus hijack enhancers and super-enhancers to dysregulate MYC expression in multiple myeloma. Leukemia 2014; 28:1725-35; Feb 12. [Epub ahead of print]; PMID:24518206; http://dx.doi.org/10.1038/leu.2014.70
   PubMed Web of Science ®Google Scholar
• Schotte D, De Menezes RX, Akbari Moqadam F, Khankahdani LM, Lange-Turenhout E, Chen C, Pieters R, Den Boer ML. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica 2011; 96(5): 703-11; PMID:21242186; http://dx.doi.org/10.3324/haematol.2010.026138
   PubMed Web of Science ®Google Scholar
• Willimott S, Wagner SD. Stromal cells and CD40 ligand (CD154) alter the miRNome and induce miRNA clusters including, miR-125b/miR-99a/let-7c and miR-17-92 in chronic lymphocytic leukaemia. Leukemia 2012; 26(5): 1113-6; PMID:22024720; http://dx.doi.org/10.1038/leu.2011.299
   PubMedGoogle Scholar
• Sun D, Layer R, Mueller AC, Cichewicz MA, Negishi M, Paschal BM, Dutta A. Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells. Oncogene 2014; 33(11): 1448-57; PMID:23503464; http://dx.doi.org/10.1038/onc.2013.77
   PubMed Web of Science ®Google Scholar
• Gong J, Zhang JP, Li B, Zeng C, You K, Chen MX, Yuan Y, Zhuang SM. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013; 32(25): 3071-9; PMID:22824797; http://dx.doi.org/10.1038/onc.2012.318
   PubMed Web of Science ®Google Scholar
• Cannizzo E, Carulli G, Del Vecchio L, Ottaviano V, Bellio E, Zenari E, Azzarà A, Petrini M, Preffer F. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model. Am J Clin Pathol 2012; 137(3): 377-86; PMID:22338049; http://dx.doi.org/10.1309/AJCP63TOCFNAMDMS
   PubMedGoogle Scholar
• Mahmoud MS, Fujii R, Ishikawa H, Kawano MM. Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 1999; 94:3551-8; PMID:10552966
   PubMed Web of Science ®Google Scholar
• Jeong TD, Park CJ, Shim H, Jang S, Chi HS, Yoon DH, Kim DY, Lee JH, Lee JH, Suh C, et al. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/ CD138 (CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells. Korean J Hematol 2012; 47:260-6; PMID:23320004; http://dx.doi.org/10.5045/kjh.2012.47.4.260
   PubMedGoogle Scholar
• Lo TF, Tsai WC, Chen ST. MicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth. PLoS One 2013; 8(9): e75628. eCollection 2013; PMID:24098708; http://dx.doi.org/10.1371/journal.pone.0075628
   PubMed Web of Science ®Google Scholar
• Qian B, Nag SA, Su Y, Voruganti S, Qin JJ, Zhang R, Cho WC. miRNAs in cancer prevention and treatment and as molecular targets for natural product anticancer agents. Curr Cancer Drug Targets 2013; 13(5): 519-41; PMID:23597193; http://dx.doi.org/10.2174/15680096113139990031
   PubMedGoogle Scholar
• Hu HY, Li KP, Wang XJ, Liu Y, Lu ZG, Dong RH, Guo HB, Zhang MX. Set9, NF-κB, and microRNA-21 mediate berberine-induced apoptosis of human multiple myeloma cells. Acta Pharmacol Sin 2013; 34(1):157-66; PMID:23247593; http://dx.doi.org/10.1038/aps.2012.161
   PubMedGoogle Scholar